Abstract
Independent studies have shown that in node negative breast cancer patients less than 71 years, the proliferation marker mitotic activity index (MAI) is the strongest, most well reproducible prognosticator and chemotherapy success predictor. The MAI overshadows the prognostic value of tubule formation, nuclear atypia and thereby grade. An often used crude mitotic impression is much less prognostic than the MAI; strict adherence to the MAI protocol is therefore important. The prognostic value of the MAI is age dependent: although patients with a MAI ≥ 10 always have a poor prognosis irrespective of age, a low MAI (<10) loses its favourable prognostic association in women >70 years. PPH3 counts are prognostically stronger than the MAI, and markers such as Cyclin-B and E2FR are promising, but must be validated. Compared with commercial prognostic gene expression signatures, the MAI is at least as strong prognostically, has far fewer false positive results and as such should be included as an independent feature in any node negative breast cancer pathology report.
Similar content being viewed by others
References
Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ et al (2003) Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 21:3357–3365. doi:10.1200/JCO.2003.04.576
Early Breast Cancer Trialists’ Collaborative Group (EBCTG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717. doi:10.1016/S0140-6736(05)66544-0
Adjuvant! Online, at http://www.adjuvantonline.com
Boyages J, Chua B, Taylor R et al (2002) Use of the St. Gallen classification for patients with node-negative breast cancer may lead to overuse of adjuvant chemotherapy. Br J Surg 89:789–796. doi:10.1046/j.1365-2168.2002.02113.x
Baak JP, van Diest PJ, Voorhorst FJ, van der Wall E, Beex LV, Vermorken JB et al (2007) The prognostic value of proliferation in lymph-node-negative breast cancer patients is age dependent. Eur J Cancer 43(3):527–535. doi:10.1016/j.ejca.2006.10.001
Baak JP, Wisse-Brekelmans EC, Kurver PH, van Gorp LH, Voorhorst FJ, Miettinen OS (1992) Regional differences in breast cancer survival are correlated with differences in differentiation and rate of proliferation. Hum Pathol 23(9):989–992. doi:10.1016/0046-8177(92)90259-6
Volpi A, De Paola F, Nanni O, Granato AM, Bajorko P, Becciolini A et al (2000) Prognostic significance of biologic markers in node-negative breast cancer patients, a prospective study. Breast Cancer Res Treat 63:181–192. doi:10.1023/A:1006464426977
Desmedt C, Sotiriou C (2006) Proliferation: the most prominent predictor of clinical outcome in breast cancer. Cell Cycle 19:2198–2202
Baak JP, van Diest PJ, Voorhorst FJ, van der Wall E, Beex LV, Vermorken JB et al (2005) Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph node-negative breast cancer patients younger than 55 years. J Clin Oncol 23(25):5993–6001. doi:10.1200/JCO.2005.05.511
Van Diest PJ, Baak JPA, Matze-Cok P, Wisse-Brekelmans EC, van Galen CM, Kurver PH et al (1992) Reproducibility of mitosis counting in 2469 breast cancer specimens, results from the multicentre morphometric mammary carcinoma project. Hum Pathol 23:603–607. doi:10.1016/0046-8177(92)90313-R
Janssen EAM, van Diest PJ, Søiland H, Gudlaugson E, Nysted A, Voorhorst FJ et al (2006) Success factors of adjuvant chemotherapy in node-negative breast cancer patients under 55 years. Cell Oncol 28(5–6):295–303
Amadori D, Nanni O, Marangolo M, Pacini P, Ravaioli A, Rossi A et al (2000) Disease-free survival advantage of adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with node-negative, rapidly proliferating breast cancer: a randomized multicenter study. J Clin Oncol 18:3125–3134
Fiets WE, Bellot FE, Struikmans H, Blankenstein MA, Nortier JW (2005) Prognostic value of mitotic counts in axillary node negative breast cancer patients with predominantly well-differentiated tumours. Eur J Surg Oncol 31(2):128–133. doi:10.1016/j.ejso.2004.08.012
Westenend PJ, Meurs CJ, Damhuis RA (2005) Tumour size and vascular invasion predict distant metastasis in stage I breast cancer. Grade distinguishes early and late metastasis. J Clin Pathol 58(2):196–201. doi:10.1136/jcp.2004.018515
Hall PA, Going JJ (1999) Predicting the future, a critical appraisal of cancer prognosis studies. Histopathology 35:489–494. doi:10.1046/j.1365-2559.1999.00862.x
Baak JP (2002) The framework of pathology, good laboratory practice by quantitative and molecular methods. J Pathol 198(3):277–283. doi:10.1002/path.1233
Baak JP, van Diest PJ, Ariens AT, van Beek MW, Bellot SM, Fijnheer J et al (1989) The Multicenter Morphometric Mammary Carcinoma Project (MMMCP). A nationwide prospective study on reproducibility and prognostic power of routine quantitative assessments in The Netherlands. Pathol Res Pract 185(5):664–670
Bullough WS (1950) Mitotic activity of the tissue in dead mice, and in tissues kept in physiological salt solutions. Exp Cell Res 1:410–420. doi:10.1016/0014-4827(50)90019-X
Graem N, Helweg-Larsen K (1979) Mitotic activity and delay in fixation of tumour tissue. The influence of delay in fixation on mitotic activity of a human osteogenic sarcoma grown in athymic nude mice. Acta Pathol Microbiol Scand [A] 87A(5):375–378
Donhuijsen K, Schmidt U, Hirsche H, van Beuningen D, Budach V (1990) Changes in mitotic rate and cell cycle fractions caused by delay in fixation. Hum Pathol 21:709–714. doi:10.1016/0046-8177(90)90030-9
Bergers E, Jannink I, van Diest PJ, Cuesta MA, Meyer S, van Mourik JC et al (1997) Influence of fixation delay on mitotic activity and flow cytometric %S-phase. Hum Pathol 28:95–100. doi:10.1016/S0046-8177(97)90286-0
Rakha EA, El-Sayed ME, Lee AH, Elston CW, Grainge MJ, Hodi Z et al (2008) Prognostic Significance of Nottingham Histologic Grade in Invasive Breast Carcinoma. J Clin Oncol 26(19):3153–3158
Ellis IO, Schnitt SJ, Sastre-Garau X, Bussolati G, Tavassoli FA, Eusebi V et al (2003) Invasive breast carcinoma. In: Tavassoli FA, Devilee P (eds) Pathology and genetics of tumours of the breast and female genital tract organs. IARC Press, Lyon, pp 18–19
Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer I. The value of histological grade in breast cancer, experience from a large study with long-term follow-up. Histopathology 19:403–410. doi:10.1111/j.1365-2559.1991.tb00229.x
Baak JP, van Diest PJ, Voorhorst FJ, van der Wall E, Beex LV, Vermorken JB, et al (2007) other collaborators of the Multicenter Morphometric Mammary Carcinoma Project (MMMCP). The prognostic value of proliferation in lymph-node-negative breast cancer patients is age dependent. Eur J Cancer 43(3):527–535. doi:10.1016/j.ejca.2006.10.001
Eppenberger-Castori S, Moore DH Jr, Thor AD, Edgerton SM, Kueng W, Eppenberger U et al (2002) Age-associated biomarker profiles of human breast cancer. Int J Biochem Cell Biol 34:1318–1330. doi:10.1016/S1357-2725(02)00052-3
Baak JP, van Diest PJ, Janssen EA, Gudlaugsson E, Voorhorst FJ, van der Wall E et al (2008) Proliferation accurately identifies the high-risk patients among small, low-grade, lymph node-negative invasive breast cancers. Ann Oncol 19(4):649–654. doi:10.1093/annonc/mdm535
Greenough RB (1925) Varying degrees of malignancy in cancer of the breast. J Cancer Res 9:425–463
Bloom HJG, Richardson WW (1957) Histological grading and prognosis in breast cancer. Br J Cancer 11:359–377
Black MM, Opler SR, Speer FD (1955) Survival in breast cancer cases in relation to the structure of the primary tumour and regional lymph nodes. Surg Gynecol Obstet 100(5):543–551
Fisher ER (1986) Prognostic and therapeutic significance of pathological features of breast cancer. NCI Monogr (1):29–34
Skaland I, van Diest PJ, Janssen EAM, Gudlaugsson E, Baak JPA (2008) Prognostic differences of WHO-assessed mitotic activity index (MAI) and mitotic impression by quick scanning in invasive ductal breast cancer patients under 55 years of age. Hum Pathol 39(4):584–590. doi:10.1016/j.humpath.2007.08.016
Jannink I, van Diest PJ, Baak JPA (1996) Comparison of the prognostic value of mitotic frequency and mitotic activity index in breast cancer. Breast 5:31–36. doi:10.1016/S0960-9776(96)90046-6
Jannink I, van Diest PJ, Baak JPA (1995) Comparison of the prognostic value of four methods to assess mitotic activity in 186 invasive breast cancer patients: classical and random mitotic activity assessments with correction for volume percentage of epithelium. Hum Pathol 26:1086–1092. doi:10.1016/0046-8177(95)90270-8
Wharton SB, Chan KK, Anderson JR, Stoeber K, Williams GH (2001) Replicative Mcm2 protein as a novel proliferation marker in oligodendrogliomas and its relationship to Ki67 labeling index, histological grade and prognosis. Neuropathol Appl Neurobiol 27:305–313. doi:10.1046/j.0305-1846.2001.00333.x
Wharton SB, Hibberd S, Eward KL, Crimmings D, Jellinek DA, Levy D et al (2004) DNA replication licensing and cell cycle kinetics of oligodendroglial tumours. Br J Cancer 91:262–269
Scott IS, Morris LS, Bird K, Davies RJ, Vowler SL, Rushbrook SM et al (2003) A novel immunohistochemical method to estimate cell-cycle phase distribution in archival tissue: implications for the prediction of outcome in colorectal cancer. J Pathol 201:187–197. doi:10.1002/path.1444
Yoshida T, Tanaka S, Mogi A, Shitara Y, Kuwano H (2004) The clinical significance of Cyclin B1 and Wee1 expression in non-small-cell lung cancer. Ann Oncol 15(2):252–256. doi:10.1093/annonc/mdh073
Dudderidge TJ, Stoeber K, Loddo M, Atkinson G, Fanshawe T, Griffiths DF et al (2005) Mcm2, geminin and Ki67 define proliferative state and are prognostic markers in renal cell carcinoma. Clin Cancer Res 11:2510–2517. doi:10.1158/1078-0432.CCR-04-1776
Shetty A, Loddo M, Fanshawe T, Prevost AT, Sainsbury R, Williams GH et al (2005) DNA replication licensing and cell cycle kinetics of normal and neoplastic breast. Br J Cancer 93:1295–1300. doi:10.1038/sj.bjc.6602829
Obermann EC, Eward KL, Dogan A, Paul EA, Loddo M, Munson P et al (2005) DNA replication licensing in peripheral B-cell lymphoma. J Pathol 205:318–328. doi:10.1002/path.1695
van Diest PJ, van der Wall E, Baak JP (2004) Prognostic value of proliferation in invasive breast cancer, a review. J Clin Pathol 57(7):675–681. doi:10.1136/jcp. 2003.010777
Skaland I, Janssen EA, Gudlaugsson E, Klos J, Kjellevold KH, Søiland H et al (2007) Phosphohistone H3 expression has much stronger prognostic value than classical prognosticators in invasive lymph node-negative breast cancer patients less than 55 years of age. Mod Pathol 20(12):1307–1315. doi:10.1038/modpathol.3800972
Brenner RM, Slayden OD, Rodgers WH et al (2003) Immunohistochemical assessment of mitotic activity with an antibody to phosphorylated histone PPH3 in the macaque and human endometrium. Hum Reprod 18:1185–1193. doi:10.1093/humrep/deg255
Juan G, Traganos F, Darzynkiewicz Z (1999) Histone PPH3 phosphorylation in human monocytes and during HL-60 cell differentiation. Exp Cell Res 246:212–220. doi:10.1006/excr.1998.4283
Bossard C, Jarry A, Colombeix C et al (2006) PPH3-based a phosphohistone PPH3 labelling for histoprognostic grading of breast adenocarcinomas and computerassisted determination of mitotic index. J Clin Pathol 59:706–710. doi:10.1136/jcp. 2005.030452
Skaland I, Janssen EAM, Gudlaugsson E, Klos J, Kjellevold KH, Søiland S, Baak JPA (2008) Validating the prognostic value of proliferation measured by Phosphohistone H3 (PPH3) in invasive lymph node-negative breast cancer patients less than 71 years of age. Breast Cancer Res Treat. 10.1007/s10549-008-9980-x
Rudolph P, Kühling H, Alm P, Fernö M, Baldetorp B, Olsson H et al (2003) Differential prognostic impact of the cyclins E and B in premenopausal and postmenopausal women with lymph node-negative breast cancer. Int J Cancer 105(5):674–680. doi:10.1002/ijc.11132
Winters ZE, Hunt NC, Bradburn MJ, Royds JA, Turley H, Harris AL et al (2001) Subcellular localisation of cyclin B, Cdc2 and p21(WAF1/CIP1) in breast cancer and association with prognosis. Eur J Cancer 37:2405–2412. doi:10.1016/S0959-8049(01)00327-6
Suzuki T, Urano T, Miki Y, Moriya T, Akahira J, Ishida T et al (2007) Nuclear cyclin B1 in human breast carcinoma as a potent prognostic factor. Cancer Sci 98:644–651. doi:10.1111/j.1349-7006.2007.00444.x
Gonzalez MA, Tachibana KK, Chin S-F, Callagy G, Madine M, Vowler SL et al (2004) Geminin predicts adverse clinical outcome in breast cancer by reflecting cell-cycle progression. J Pathol 204:121–130. doi:10.1002/path.1625
Gonzalez MA, Pinder SE, Callagy G, Vowler SL, Morris LS, Bird K et al (2003) Minichromosome maintenance protein 2 is strong independent prognostic marker in breast cancer. J Clin Oncol 21:4306–4313. doi:10.1200/JCO.2003.04.121
Björck E, Ek S, Landgren O, Jerkeman M, Ehinger M, Björkholm M et al (2005) High expression of cyclin B1 predicts a favorable outcome in patients with follicular lymphoma. Blood 105:2908–2915. doi:10.1182/blood-2004-07-2721
Vuaroqueaux V, Urban P, Labuhn M, Delorenzi M, Wirapati P, Benz CC et al (2007) Low E2F1 transcript levels are a strong determinant of favorable breast cancer outcome. Breast Cancer Res 9(3):R33. doi:10.1186/bcr1681
Janicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M et al (2001) Randomized adjuvant chemotherapy trial in high-risk, lymph nodenegative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 93:913–920. doi:10.1093/jnci/93.12.913
Look M, van Putten W, Duffy M, Harbeck N, Christensen IJ, Thomssen C et al (2003) Pooled analysis of prognostic impact of uPA and PAI-1 in breast cancer patients. Thromb Haemost 90:538–548
Zemzoum I, Kates RE, Ross JS, Dettmar P, Dutta M, Henrichs C et al (2003) Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer. J Clin Oncol 21:1022–1028. doi:10.1200/JCO.2003.04.170
Cady B (1997) New era in breast cancer. Impact of screening on disease presentation. Surg Oncol Clin N Am 6:195–202
Han B, Nakamura M, Mori I, Nakamura Y, Kakudo K (2005) Urokinase type plasminogen activator system and breast cancer. Oncol Rep 14:105–112 Review
Leissner P, Verjat T, Bachelot T, Paye M, Krause A, Puisieux A et al (2006) Prognostic significance of urokinase plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in lymph node- and hormone receptor-positive breast cancer. BMC Cancer 6:216. doi:10.1186/1471-2407-6-216
Urban P, Vuaroqueaux V, Labuhn M, Delorenzi M, Wirapati P, Wight E et al (2006) Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer. J Clin Oncol 24(26):4245–4253. doi:10.1200/JCO.2005.05.1912
Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA et al (2000) Molecular protraits of human breast tumours. Nature 406:747–752. doi:10.1038/35021093
Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869–10874. doi:10.1073/pnas.191367098
Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, Nobel AB et al (2006) Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 355(6):560–569. doi:10.1056/NEJMoa052933
Farrow SN, Brown R (1996) New members of the Bcl-2 family and their protein partners. Curr Opin Genet Dev 6:45–49. doi:10.1016/S0959-437X(96)90009-X
Yang E, Korsmeyer SJ (1996) Molecular thanatopsis: a discourse on the Bcl-2 family and cell death. Blood 88:386–401
Minn AJ, Boise LH, Thompson CB (1996) Bcl-xS antagonizes the protective effects of Bcl-xL. J Biol Chem 271:6306–6312. doi:10.1074/jbc.271.11.6306
Miyashita T, Kitada S, Krajewski S, Horne WA, Delia D, Reed JC (1995) Overexpression of Bcl-2 protein increases the half-life of p21 (Bax). J Biol Chem 270:26049–26052. doi:10.1074/jbc.270.44.26049
Doglioni C, Dei Tos AP, Laurino L, Chiarelli C, Barbareschi M et al (1994) The prevalence of Bcl-2 immunoreactivity in breast carcinomas and its clinicopathological correlations, with particular reference to estrogen receptor status. Virchows Arch 424:47–51. doi:10.1007/BF00197392
Krajewski S, Krajewska M, Shabaik A, Miyashita T, Wang HG, Reed JC (1994) Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2. Am J Pathol 145:1323–1336
Krajewski S, Blomqvist C, Franssila K, Krajewska M, Wasenius VM, Niskanen E et al (1995) Reduced expression of the proapoptotic gene BAX is associated with poor response rates to combined chemotherapy and shortened survival in women with metastatic breast adenocarcinoma. Cancer Res 55:4471–4478
Barbareschi M, Caffo O, Veronese S, Leek RD, Fina P, Fox S et al (1996) Bcl-2 and p53 expression in node-negative breast carcinoma: a study with long-term follow-up. Hum Pathol 27:1149–1155. doi:10.1016/S0046-8177(96)90307-X
Bargou RC, Dainel PT, Mapara MY, Bommert K, Wagener C, Killinich B et al (1995) Expression of the bcl-2 gene family in normal and malignant breast tissue: low bax-alpha expression in tumor cells correlates with resistance towards apoptosis. Int J Cancer 60:854–859. doi:10.1002/ijc.2910600622
Kapucuoglu N, Losi L, Eusebi V (1997) Immunohistochemical localization of Bcl-2 and Bax proteins in in situ and invasive breast carcinomas. Virchows Arch 430:17–22. doi:10.1007/BF01008011
Sierra A, Castellsagué X, Coll T, Mañas S, Escobedo A, Moreno A et al (1998) Expression of death-related genes and their relationship to loss of apoptosis in T1 ductal breast carcinomas. Int J Cancer 79:103–110. doi:10.1002/(SICI)1097-0215(19980417)79:2<103::AID-IJC1>3.0.CO;2-X
Veronese S, Mauri FA, Caffo O, Scaioli M, Aldovini D, Perrone G et al (1998) Bax immunohistochemical expression in breast carcinoma: a study with long term follow-up. Int J Cancer 79:13–18. doi:10.1002/(SICI)1097-0215(19980220)79:1<13::AID-IJC3>3.0.CO;2-Z
van Slooten HJ, van de Vijver MJ, van de Velde CJ, van Dierendonck JH (1998) Loss of Bcl-2 in invasive breast cancer is associated with high rates of cell death, but also with increased proliferation activity. Br J Cancer 77:789–796
de Jong JS, van Diest PJ, Baak JPA (2000) Number of apoptotic cells as a prognostic marker in invasive breast cancer. Br J Cancer 82:368–373. doi:10.1054/bjoc.1999.0928
Gasparini G (1996) Clinical significance of the determination of angiogenesis in human breast cancer: update of the biological background and overview of the Vincenza studies. Eur J Cancer 32A:2485–2493. doi:10.1016/S0959-8049(96)00376-0
Vermeulen PB, Gasparini G, Fox SB, Toi M, Martin L, McCulloch P et al (1996) Quantification of angiogenesis in solid human tumors: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 32A:2472–2484
Weidner N, Semple JP, Welch WR, Folkman J (1991) Tumor angiogenesis and metastasis—correlation in invasive breast carcinoma. N Engl J Med 324:1–8
de Jong JS, van Diest PJ, Baak JPA (2000) Hot spot microvessel density and the mitotic activity index are strong additional prognostic indicators in invasive breast cancer. Histopathology 36:306–312. doi:10.1046/j.1365-2559.2000.00850.x
Stefansson IM, Salvesen HB, Akslen LA (2006) Vascular proliferation is important for clinical progress of endometrial cancer. Cancer Res 66(6):3303–3309. doi:10.1158/0008-5472.CAN-05-1163
Papadopoulos I, Giatromanolaki A, Koukourakis MI, Sivridis E (2004) Tumour angiogenic activity and vascular survival ability in bladder carcinoma. J Clin Pathol 57(3):250–255. doi:10.1136/jcp. 2003.012005
Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ (2005) Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16:1569–1583. doi:10.1093/annonc/mdi326
Marinho V, Metze K, Sanches F, Rocha G, Gobbi H (2008) Lymph vascular invasion in invasive mammary carcinomas identified by the endothelial lymphatic marker D2-40 is associated with other indicators of poor prognosis. BMC Cancer 8:64. doi:10.1186/1471-2407-8-64
Søiland H, Skaland I, Van Diermen B, Janssen E, Körner H, Varhaug JE et al (2007) Androgen receptor determination in breast cancer: a comparison of the dextran-coated charcoal method and quantitative immunohistochemical analysis. AIMM (Sep):19 (accepted for publication)
Rabban JT, Chen Y (2008) D2-40 expression by breast myoepithelium: potential pitfalls in distinguishing intralymphatic carcinoma from in situ carcinoma. Hum Pathol 39:175–183. doi:10.1016/j.humpath.2007.06.018
Reis-Filho JS, Simpson PT, Gale T, Lakhani SR (2005) The molecular genetics of breast cancer: the contribution of comparative genomic hybridization. Pathol Res Pract 201(11):713–725. doi:10.1016/j.prp. 2005.05.013
Kallioniemi A, Kallioniemi OP, Sudar D, Rutovitz D, Gray JW, Waldman F et al (1992) Comparative genomic hybridization for molecular cytogenetic analysis of solid tumours. Science 258:818–821. doi:10.1126/science.1359641
Weiss MM, Hermsen MA, Meijer GA, van Grieken NC, Baak JP, Kuipers EJ et al (1999) Comparative genomic hybridisation. Mol Pathol 52(5):243–251
Janssen EA, Baak JP, Guervós MA, van Diest PJ, Jiwa M, Hermsen MA (2003) In lymph node-negative invasive breast carcinomas, specific chromosomal aberrations are strongly associated with high mitotic activity and predict outcome more accurately than grade, tumour diameter, and oestrogen receptor. J Pathol 201(4):555–561. doi:10.1002/path.1475
Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A et al (2003) Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 100(18):10393–10398. doi:10.1073/pnas.1732912100
Bertucci F, Orsetti B, Nègre V, Finetti P, Rougé C, Ahomadegbe JC et al (2008) Lobular and ductal carcinomas of the breast have distinct genomic and expression profiles. Oncogene. [Epub ahead of print]
Melchor L, Honrado E, García MJ, Alvarez S, Palacios J, Osorio A et al (2008) Distinct genomic aberration patterns are found in familial breast cancer associated with different immunohistochemical subtypes. Oncogene 27(22):3165–3175. doi:10.1038/sj.onc.1210975
van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999–2009. doi:10.1056/NEJMoa021967
Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F et al (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365(9460):671–679
Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817–2826. doi:10.1056/NEJMoa041588
Ma XJ, Wang Z, Ryan PD, Isakoff SJ, Barmettler A, Fuller A et al (2004) A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5(6):607–616. doi:10.1016/j.ccr.2004.05.015
Buyse M, Loi S, van’t Veer L, Viale G, Delorenzi M, Glas AM et al (2006) Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Nat Can Inst 98:1183–1192
Goncalves A, Esterni B, Bertucci F, Sauvan R, Chabannon C, Cubizolles M et al (2006) Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy. Oncogene 25:981–989. doi:10.1038/sj.onc.1209131
Ricolleau G, Lode Charbonnel C, Loussouarn D, Joalland MP, Bogumil R et al (2006) Surface-enhanced laser desorption/ionization time of flight mass spectrometry protein profiling identifies ubiquitin and ferritin light chain as prognostic biomarkers in node-negative breast cancer tumors. Proteomics 6:1963–1975
Jacquemier J, Ginestier C, Rougemont J, Bardou VJ, Charafe-Jauffret E, Geneix J et al (2005) Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. Cancer Res 65:767–779
Acknowledgement
Financial support: Supported by a grant from the Folke Hermansen Foundation, 2007.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Baak, J.P.A., Gudlaugsson, E., Skaland, I. et al. Proliferation is the strongest prognosticator in node-negative breast cancer: significance, error sources, alternatives and comparison with molecular prognostic markers. Breast Cancer Res Treat 115, 241–254 (2009). https://doi.org/10.1007/s10549-008-0126-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-008-0126-y